Cancer最新文献

{"title":"Dr V. Craig Jordan, PhD, DSc, FAACR","authors":"Debra A. Tonetti PhD, Clodia Osipo PhD, Ruth M. O’Regan MD, MSc","doi":"10.1002/cncr.35643","DOIUrl":"10.1002/cncr.35643","url":null,"abstract":"<p>Dr V. Craig Jordan, PhD, DSc, FAACR, the “Father of Tamoxifen,” passed away on June 9, 2024, at 76 years of age (Figure 1).</p><p>Born in Texas, Dr Jordan grew up in England. He earned doctorates in chemistry and science from the University of Leeds. During this time, he started working with ICI Pharmaceuticals (now AstraZeneca) on ICI 46474, the blockbuster drug tamoxifen. Initially developed as a contraceptive, ICI 46474 was actually found to enhance fertility. Dr Jordan was the first to note its efficacy against breast cancer, and he spent 2 years at the Worcester Foundation for Experimental Biology in Massachusetts evaluating tamoxifen as a potential treatment for breast cancer. He then returned to Leeds as a lecturer in pharmacology. After a year at the Ludwig Institute in Bern, Switzerland, he joined the faculty at the University of Wisconsin–Madison. In 1993, he was recruited to Northwestern University as professor of cancer pharmacology and director of the Breast Cancer Research Program at the Robert H. Lurie Comprehensive Cancer Center. During his time at Northwestern, he was appointed as the inaugural Diana, Princess of Wales Professor of Cancer Research and led a successful breast cancer Specialized Program of Research Excellence (SPORE) grant. In 2005, he joined the Fox Chase Cancer Center as the Alfred G. Knudson Chair of Cancer Research, and in 2009 moved to Georgetown University as professor of oncology and pharmacology and scientific director of the Lombardi Comprehensive Cancer Center. In 2014, he moved back to Texas as professor of medical oncology and molecular and cellular oncology at the MD Anderson Cancer Center.</p><p>Dr Jordan’s considerable contributions to breast cancer have significantly affected the lives of many thousands of women with breast cancer and have been recognized by multiple awards, including the Medal of Honor for Basic Research from the American Cancer Society, the Charles F. Kettering Prize from the General Motors Cancer Research Foundation, and the American Society of Clinical Oncology David A. Karnofsky Award. He was elected a member of the National Academy of Sciences and the National Academy of Medicine. In 2002, Queen Elizabeth II made him an officer of the Order of the British Empire, and a companion of the Order of St. Michael and St. George in 2019.</p><p>One of Dr Jordan’s greatest strengths was his ability to build teams that remain intact even through today. We were all closely mentored by Dr Jordan, and we took what we learned and applied it to one another. As an example, Dr O’Regan joined the Jordan team during her fellowship, with absolutely zero laboratory experience. Dr Jordan linked her up with Dr Tonetti, who painlessly mentored her on basic laboratory experiments throughout her time at Northwestern. He was an expert in training the mentee to become a mentor. All three of us spent our early careers as part of the Jordan “Tamoxifen Team,” and each of us is now a tenured professor at o","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35643","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142764722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy recommendation, initiation, and completion: Complex questions of access and equity","authors":"Edward Christopher Dee MD, Erin Jay G. Feliciano MD, MBA, Nina N. Sanford MD, Puneeth Iyengar MD PhD","doi":"10.1002/cncr.35654","DOIUrl":"10.1002/cncr.35654","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142764733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024","authors":"Alan H. Bryce MD,&nbsp;Neeraj Agarwal MD,&nbsp;Himisha Beltran MD,&nbsp;Maha H. Hussain MD,&nbsp;Oliver Sartor MD,&nbsp;Neal Shore MD,&nbsp;Emmanuel S. Antonarakis MD,&nbsp;Andrew J. Armstrong MD, MSc,&nbsp;Jeremie Calais MD, PhD,&nbsp;Michael A. Carducci MD,&nbsp;Tanya Barauskas Dorff MD,&nbsp;Jason A. Efstathiou MD, DPhil,&nbsp;Martin Gleave MD,&nbsp;Leonard G. Gomella MD,&nbsp;Celestia Higano MD,&nbsp;Thomas A. Hope MD,&nbsp;Andrei Iagaru MD,&nbsp;Alicia K. Morgans MD, MPH,&nbsp;David S. Morris MD,&nbsp;Michael J. Morris MD,&nbsp;Daniel P. Petrylak MD,&nbsp;Robert E. Reiter MD,&nbsp;Matthew B. Rettig MD, MBA,&nbsp;Charles J. Ryan MD,&nbsp;Scott B. Sellinger MD,&nbsp;Daniel E. Spratt MD,&nbsp;Sandy Srinivas MD,&nbsp;Scott T. Tagawa MD, MS,&nbsp;Mary-Ellen Taplin MD,&nbsp;Evan Y. Yu MD,&nbsp;Tian Zhang MD,&nbsp;Rana R. McKay MD,&nbsp;Phillip J. Koo MD,&nbsp;E. David Crawford MD","doi":"10.1002/cncr.35612","DOIUrl":"10.1002/cncr.35612","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142764730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety","authors":"Lucia Masarova MD,&nbsp;John Mascarenhas MD, MS,&nbsp;Raajit Rampal MD, PhD,&nbsp;Wilson Hu MD,&nbsp;Robert A. Livingston MD, MPH,&nbsp;Naveen Pemmaraju MD","doi":"10.1002/cncr.35661","DOIUrl":"10.1002/cncr.35661","url":null,"abstract":"<p>The oral Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib was approved by the US Food and Drug Administration in 2014 for treatment of patients with polycythemia vera (PV) who have an inadequate response to or intolerance of hydroxyurea (HU). PV is a chronic myeloproliferative neoplasm defined by primary absolute erythrocytosis, bone marrow hypercellularity, and JAK mutations such as <i>JAK2</i>V617F. Patients with PV experience burdensome symptoms and are at risk of thromboembolic events, in particular those with resistance to or intolerance of initial treatments such as HU. Other risks for patients with PV include progression of disease to more aggressive forms with worse prognoses, such as myelofibrosis or blast-phase myeloproliferative neoplasms. This review summarizes the efficacy and safety of ruxolitinib from key phase 2 and 3 trials (MAJIC-PV, RESPONSE, RESPONSE-2, RELIEF, and Ruxo-BEAT), large real-world studies, and a decade of postmarketing surveillance safety data. The authors focus on improved blood count control, rates of thromboembolic events, symptom improvement, and markers of disease modification such as reduction of <i>JAK2</i>V617F allele burden in patients treated with ruxolitinib. They also discuss the well-characterized safety profile of ruxolitinib regarding hematologic and other adverse events of interest. In the 10 years since its approval, ruxolitinib remains a safe and effective standard-of-care treatment for PV. As the treatment landscape for PV continues to evolve in the coming years, the efficacy and safety profiles of ruxolitinib suggest it will remain a preferred treatment as monotherapy and as a potential backbone of future combination regimens.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142764753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social capital as a catalyst for gender inequality: A scoping review of networking disparities in academic medicine","authors":"Jacquelyn K. Callander MD,&nbsp;Daniel E. Johnson PhD,&nbsp;Jennifer R. Grandis MD","doi":"10.1002/cncr.35667","DOIUrl":"10.1002/cncr.35667","url":null,"abstract":"<p>Gender disparities in academic medicine persist despite gender parity among medical school graduates. Women remain underrepresented in higher academic ranks and leadership roles, with significant differences in retention, promotion, and compensation. In this scoping review, the authors explore the role of networking and social capital in exacerbating these disparities. The literature reviewed highlights the importance of networking in obtaining leadership roles, decreasing social isolation, and enhancing retention. Sponsorship, distinct from mentorship, is vital for career development and has a direct impact on professional growth. However, women are often under-sponsored compared with men, limiting their access to influential networks. In addition, virtual networking platforms and women-focused organizations offer promising alternatives to traditional, male-dominated networking activities. Despite the progress made, informal networking practices and gender biases continue to exclude women from key opportunities. These findings underscore the need for targeted interventions aimed at enhancing the social capital of women in academic medicine to help close the gender gap. Proposed interventions prime for further evaluation include the implementation of formal sponsorship programs, the development of structured networking opportunities, and the promotion of women-focused organizations.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation","authors":"Bryson W. Katona MD,&nbsp;Jan Lubinski MD,&nbsp;Tuya Pal MD,&nbsp;Tomasz Huzarski MD,&nbsp;William D. Foulkes MD,&nbsp;Pal Moller MD,&nbsp;Andrea Eisen MD,&nbsp;Susan Randall Armel MSc,&nbsp;Susan L. Neuhausen PhD,&nbsp;Rebecca Raj BSc,&nbsp;Amber Aeilts MSc,&nbsp;Christian F. Singer MD,&nbsp;Louise Bordeleau MD,&nbsp;Beth Karlan MD,&nbsp;Olufunmilayo Olopade MD,&nbsp;Nadine Tung MD,&nbsp;Dana Zakalik MD,&nbsp;Joanne Kotsopoulos PhD,&nbsp;Robert Fruscio MD,&nbsp;Charis Eng MD,&nbsp;Ping Sun PhD,&nbsp;Steven A. Narod MD,&nbsp;the Hereditary Breast Cancer Clinical Study Group","doi":"10.1002/cncr.35666","DOIUrl":"10.1002/cncr.35666","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The lifetime risk of pancreatic cancer in women with a germline mutation in <i>BRCA1</i> and <i>BRCA2</i> is not well established. In an international prospective cohort of female carriers of <i>BRCA1</i> and <i>BRCA2</i> mutations, the cumulative incidence of pancreatic cancer from age 40 until 80 years was estimated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 8295 women with a <i>BRCA1</i> or <i>BRCA2</i> mutation were followed for new cases of pancreatic cancer. Subjects were followed from the date of baseline questionnaire or age 40 years (whichever came last) until a new diagnosis of pancreatic cancer, death from another cause, or date of last follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty-four incident pancreatic cancer cases were identified in the cohort. The annual risk of pancreatic cancer between age 40 and 80 years was 0.04% for <i>BRCA1</i> carriers and 0.09% for <i>BRCA2</i> carriers. Via the Kaplan–Meier method, the cumulative incidence from age 40 to 80 years was 2.2% (95% CI, 1.1%–4.3%) for <i>BRCA1</i> carriers and 2.7% (95% CI, 1.3%–5.4%) for <i>BRCA2</i> carriers. Only two of the 34 cases reported a first-degree relative with pancreatic cancer (hazard ratio, 4.75; 95% CI, 1.13–19.9; <i>p</i> = .03). Risk factors for pancreatic cancer included alcohol intake and a history of diabetes. The 5-year survival rate for the 34 cases was 8.8%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The lifetime risk of pancreatic cancer is approximately 2% in women with a <i>BRCA1</i> mutation and 3% for women with a <i>BRCA2</i> mutation. The poor survival in hereditary pancreatic cancer underscores the need for novel antitumoral strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive care for patients with bladder cancer: Addressing the interplay of physical, nutritional, and emotional well-being","authors":"Cristiane Decat Bergerot PhD,&nbsp;Kathryn H. Schmitz PhD,&nbsp;Tracy E. Crane PhD,&nbsp;Zachary Klaassen MD, MSc,&nbsp;Paulo Gustavo Bergerot MD","doi":"10.1002/cncr.35670","DOIUrl":"10.1002/cncr.35670","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142737751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vascular endothelial growth factor and programmed cell death-1 inhibition in bone sarcomas","authors":"Daniel Reinhorn,&nbsp;Sandra P. D’Angelo","doi":"10.1002/cncr.35668","DOIUrl":"10.1002/cncr.35668","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142737753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Tuskegee: A contemporary qualitative assessment of barriers to research participation among Black women","authors":"Jeuneviette E. Bontemps-Jones MPH,&nbsp;Lauren E. McCullough PhD, MSPH,&nbsp;Elizabeth G. Kirkland MPH,&nbsp;Lauren R. Teras PhD,&nbsp;Peter Briggs MPH,&nbsp;Melicia C. Whitt-Glover PhD, FACSM,&nbsp;Shavon Arline-Bradley MPH, MDiv,&nbsp;Jamal Winn BS,&nbsp;Jason Lett BS,&nbsp;Alpa V. Patel PhD","doi":"10.1002/cncr.35648","DOIUrl":"10.1002/cncr.35648","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Health care inequities have partially contributed to the existing racial gaps in health. Despite having lower incidence rates of breast cancer, Black women have a 41% higher mortality rate than White women. Black individuals remain underrepresented in research. Diversity in research is paramount to the improvement of clinical care practices and subgroup-specific guidelines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Black women from various community venues across geographic regions of the United States were invited via email, online fliers, social media platforms, and word of mouth to participate in focus groups. Six online focus groups of six to 10 Black women aged 25–65 years (<i>N</i> = 38) with and without a history of cancer were conducted with an in-depth semistructured discussion guide.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Most participants were college educated (32 of 38; 84.2%), aged 50 years or older (31 of 38; 81.6%), and had an annual income of $50,000 or more (26 of 38; 68.4%). Several barriers to research participation were identified. They included a lack of empathy and respect in health care settings, apprehension regarding the sharing of personal information, mistrust of medical research, and logistical/technical barriers. Alternatively, building individual and community trust and communicating the value of conducting research beneficial to the Black community were viewed as facilitators to research participation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Successful engagement of Black women in research requires the acknowledgment and consideration of the numerous barriers that affect their ability to participate. Black women are more inclined to participate in research when the research team is knowledgeable, has experience within their communities, and engages trusted community partners. Additionally, the research must be meaningful and impactful to future generations of Black women.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142724344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib therapy","authors":"Lu Yu MD,&nbsp;Weiming Li MD,&nbsp;Na Xu MD,&nbsp;Xiaoli Liu MD,&nbsp;Bingcheng Liu MD,&nbsp;Yanli Zhang MD,&nbsp;Li Meng MD,&nbsp;Huanling Zhu MD,&nbsp;Xin Du MD,&nbsp;Suning Chen MD,&nbsp;Yu Hu MD,&nbsp;Yongping Song MD,&nbsp;Lichuang Men MSc,&nbsp;Qian Jiang MD","doi":"10.1002/cncr.35652","DOIUrl":"10.1002/cncr.35652","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The objective of this study was to assess patient-reported outcomes (PROs), including health-related quality of life (HRQoL) and anxiety and depression symptoms, and to identify associated variables in patients with tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia (CML) in chronic-phase (CP) or accelerated-phase (AP) who were receiving olverembatinib.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients in multicenter studies were invited to complete the European Organization for Research and Treatment of Cancer Quality-of-Life Core 30 Questionnaire, the Self-Rating Anxiety Scale, and the Self-Rating Depression Scale at baseline and regularly during olverembatinib therapy. The time trends in PROs were estimated with a linear model using a generalized estimating equation based on an independent working correlation matrix. A generalized estimating equation model was used to assess the variables associated with PROs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 146 patients with CML-CP or CML-AP were included in this study. Scores on seven items from the European Organization for Research and Treatment of Cancer Quality-of-Life Core 30 Questionnaire, including global health, physical functioning, emotional functioning, fatigue, dyspnea, diarrhea, and financial difficulties, improved significantly over time during olverembatinib therapy. In multivariate analysis, age younger than 40 years was significantly associated with greater improvement in social functioning (<i>p</i> = .033), and CML-CP (vs. CML-AP) was associated with greater improvements in dyspnea (<i>p</i> = .031) and diarrhea (<i>p</i> = .031) over time. Scores on the Self-Rating Anxiety Scale and the Self-Rating Depression Scale decreased significantly over time during olverembatinib treatment (<i>p</i> &lt; .001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The authors concluded that HRQoL significantly improved over time during olverembatinib therapy in heavily treated patients with TKI-resistant CML, especially among those who were younger and those who had CML-CP. Anxiety symptoms also significantly decreased over time.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142724348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}